Integrating the knowledge of cellular immunology, regulatory biology, molecular biology, peptide chemistry, and protein scaffold technology, we are designing an innovative new generation of anti-allergy drugs with high efficacies and large safety margins. The treatment leads to substantially lower levels of IgE and prevents the activation of IgE sensitized mast cells. The second generation of IgE therapeutics aims at altering the natural course of allergic asthma.